Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.58 USD
Change Today 0.00 / 0.00%
Volume 0.0
RSWN On Other Exchanges
Symbol
Exchange
OTC US
As of 8:10 PM 05/4/15 All times are local (Market data is delayed by at least 15 minutes).

rosewind corp (RSWN) Snapshot

Open
$0.58
Previous Close
$0.58
Day High
$0.58
Day Low
$0.58
52 Week High
04/24/15 - $0.97
52 Week Low
01/21/15 - $0.16
Market Cap
100.7M
Average Volume 10 Days
14.1K
EPS TTM
--
Shares Outstanding
173.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ROSEWIND CORP (RSWN)

Related News

No related news articles were found.

rosewind corp (RSWN) Related Businessweek News

No Related Businessweek News Found

rosewind corp (RSWN) Details

Rosewind Corporation, a development stage company, focuses on the development of late-stage therapeutics for urological and related conditions. Its lead therapeutic candidate, Zertane, is a treatment for premature ejaculation (PE) that is nearing commercial-stage; and the RedoxSYS System, which has CE marking for Europe and medical device approval by Health Canada for the treatment of male infertility. The company was founded in 2002 and is based in Loveland, Colorado.

1 Employees
Last Reported Date: 11/26/14
Founded in 2002

rosewind corp (RSWN) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

rosewind corp (RSWN) Key Developments

Rosewind Corporation Announces Management Appointments

On April 16, 2015, Luoxis Diagnostics Inc. and Vyrix, each previously a subsidiary of Ampio, entered into an agreement and plan of merger by and among Rosewind Corporation, Luoxis, Vyrix, two major stockholders of Rosewind and two subsidiaries of Rosewind created solely for the purposes of the merger. On April 16, 2015, Joshua R. Disbrow resigned as Chief Operating Officer of Ampio in connection with the merger to assume the role of Chief Executive Officer of Rosewind, and Jarrett Disbrow resigned as President and Chief Executive Officer of Vyrix Pharmaceuticals to assume the role of Chief Operating Officer of Rosewind.

Rosewind Corp, Luoxis Diagnostics Inc., Vyrix Pharmaceuticals, Inc. - M&A Call

To discuss merger between Rosewind Corporation, Vyrix Pharmaceuticals and Luoxis Diagnostics

Rosewind Corp Auditor Raises 'Going Concern' Doubt

Rosewind Corp filed its 10-K on Nov 26, 2014 for the period ending Aug 31, 2014. In this report its auditor, H J & Associates, LLC, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RSWN:US $0.58 USD 0.00

RSWN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RSWN.
View Industry Companies
 

Industry Analysis

RSWN

Industry Average

Valuation RSWN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2,625.9x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 8,709.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ROSEWIND CORP, please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.